Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.
Chang, Seong Sil; Suratwala, Sanjeev J; Jung, Kwang Mook; Doppelt, Jason D; Zhang, Hui Zhu; Blaine, Theodore A; Kim, Tae Wan; Winchester, Robert J; Lee, Francis Young-In.
Clin Orthop Relat Res
; (426): 103-9, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15346059
A mouse model of luciferase-transfected stromal cells of giant cell tumor of bone.
Bisphosphonates and other bone agents for breast cancer.
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Können 12- statt 4wöchentliche Zoledronsäuregaben skelettale Ereignisse bei Patienten mit Knochenmetastasen reduzieren?
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Significance of ß-catenin expression for the incidence of pathological fractures in giant cell tumors of bone.
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Increased Risk of Lung Metastases in Patients with Giant Cell Bone Tumors: A Systematic Review.